| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 07/06/2004 | US6759035 Method to prevent graft rejection using TGF-beta to induce T suppressor cells |
| 07/06/2004 | CA2085201C New pyridyl derivatives, pharmaceutical compositions containing these compounds and processes for preparing them |
| 07/01/2004 | WO2004055513A2 Use of cd137 antagonists for the treatment of tumors |
| 07/01/2004 | WO2004055185A1 Novel protein and dna thereof |
| 07/01/2004 | WO2004055043A1 Epitopic peptides of the thyroperoxidase enzyme, compositions containing same and uses thereof |
| 07/01/2004 | WO2004055042A1 Biologically active peptide conjugates |
| 07/01/2004 | WO2004055014A1 Tetracyclic immunomodulatory compounds |
| 07/01/2004 | WO2004054973A2 Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor |
| 07/01/2004 | WO2004054616A1 Antagonist and agonist binding to strong binding site of chemokine receptor |
| 07/01/2004 | WO2004054577A1 Alpha-2-delta ligands to treat ocd and related diseases |
| 07/01/2004 | WO2004054563A1 Alpha-2-delta ligand for the treatment of sexual dysfunction |
| 07/01/2004 | WO2004054559A1 Alpha2delta ligands for different pharmaceutical uses |
| 07/01/2004 | WO2004054514A2 C-6 modified indazolylpyrrolotriazines |
| 07/01/2004 | WO2004020014A3 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 07/01/2004 | WO2004018058A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004013093A3 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 07/01/2004 | WO2004006865A3 Compounds, compositions, and methods |
| 07/01/2004 | WO2004002420A3 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 07/01/2004 | WO2004001007A3 Buffered formulations for concentrating antibodies and methods of use thereof |
| 07/01/2004 | WO2003093297A3 Protein kinase modulators and methods of use |
| 07/01/2004 | WO2003092605A3 Protease inhibitors |
| 07/01/2004 | WO2003086325A3 Cyanamides useful as reversible inhibitors of cysteine proteases |
| 07/01/2004 | WO2003057822A9 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| 07/01/2004 | WO2003045369A9 Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses |
| 07/01/2004 | WO2002062834A3 Mixture of peptides originating from a nef protein and applications thereof |
| 07/01/2004 | US20040127712 Aminoalkyl-3, 4-dihydroquinoline derivatives as no-synthase inhibitors |
| 07/01/2004 | US20040127707 Novel phthalazinones |
| 07/01/2004 | US20040127696 Growth differentiation factor-7 |
| 07/01/2004 | US20040127576 Estrogen receptor modulators |
| 07/01/2004 | US20040127544 Mannich base prodrugs of 3-(Pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127542 1-(Pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 07/01/2004 | US20040127538 having an excellent JNK inhibitory action |
| 07/01/2004 | US20040127537 Stable liquid parenteral parecoxib formulation |
| 07/01/2004 | US20040127534 Cellular adhesion molecule and leukointegrin inhibitors; inflammatory diseases; more slowly metabolized |
| 07/01/2004 | US20040127532 Method for synthesizing leflunomide |
| 07/01/2004 | US20040127528 Metalloproteinase inhibitors |
| 07/01/2004 | US20040127517 For therapy of treat atherosclerosis, autoimmune diseases, multiple sclerosis), asthma, rheumatoid arthritis, fibrotic diseases, idiopathic pulmonary fibrosis, cystic fibrosis, glumerulonephritis, rheumatoid spondylitis, osteoarthritis, gout |
| 07/01/2004 | US20040127513 For prophylaxis and therapy of chronic or acute inflammatory or autoimmune diseases, those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease |
| 07/01/2004 | US20040127508 Substituted pyrazolopyrimidines and thiazolopyrimidines |
| 07/01/2004 | US20040127495 Preferential suppressors of immunoglobulins, used as immunosuppressants and antiallergens |
| 07/01/2004 | US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 |
| 07/01/2004 | US20040127485 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists |
| 07/01/2004 | US20040127481 Administering a therapeutic amount of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol |
| 07/01/2004 | US20040127468 phosphatidic acid decreases apoptosis induced by the sudden withdrawal of NGF and serum (trophic withdrawal), rotenone, and glutamate |
| 07/01/2004 | US20040127455 Muscosal immunoregulatory agent and its use |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040127435 Uses for inhibitors of inosine monophosphate dehydrogenase |
| 07/01/2004 | US20040127429 glycolipid ligand for natural killer T (NKT) cells; synthetic analogs of alpha -C-galactosylceramides |
| 07/01/2004 | US20040127408 based on the complementarity-determining region (CDR) of a human monoclonal anti-DNA antibody |
| 07/01/2004 | US20040127404 Methods for treating autoimmune diseases |
| 07/01/2004 | US20040126870 Ncc2705-the genome of a bifodobacterium |
| 07/01/2004 | US20040126859 Mutant forms of Fas ligand and uses thereof |
| 07/01/2004 | US20040126799 First nucleotide sequence comprises adenine residue at position 1033 or equivalent; reducing disease treatment side effects |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126394 Novel composition |
| 07/01/2004 | US20040126363 Cd19-specific redirected immune cells |
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | US20040126329 Delivery of analgesics through an inhalation route |
| 07/01/2004 | US20040126328 Arerosol; heating drug, vaporization, cooling |
| 07/01/2004 | US20040126327 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 07/01/2004 | US20040126326 Delivery of antidepressants through an inhalation route |
| 07/01/2004 | CA2840513A1 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom |
| 07/01/2004 | CA2779684A1 Immunization of fish with plant-expressed recombinant proteins |
| 07/01/2004 | CA2509611A1 Method of treatment for sexual dysfunction |
| 07/01/2004 | CA2509600A1 Pharmaceutical uses for alpha2delta ligands |
| 06/30/2004 | EP1433792A2 Human receptor proteins, related reagents and methods |
| 06/30/2004 | EP1433781A1 Pyrrolidine carboxylic acid derivatives |
| 06/30/2004 | EP1432991A1 Identification and isolation of somatic stem cells and uses thereof |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432791A1 Alphavirus replicon vector systems |
| 06/30/2004 | EP1432735A2 Antagonistic anti-htnfsf13b human antibodies |
| 06/30/2004 | EP1432734A1 Cytokine receptor |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432723A2 Modulation of the expression of genes dependent on stat-1 |
| 06/30/2004 | EP1432715A2 Pyrimidine derivatives |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432700A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432445A2 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex |
| 06/30/2004 | EP1432441A2 Use of hmgb1 for the activation of dendritic cells |
| 06/30/2004 | EP1432440A2 Adjuvants for nucleic acid vaccines |
| 06/30/2004 | EP1432436A2 Nutrient therapy for immuno-compromised patients |
| 06/30/2004 | EP1432435A1 Enamel matrix protein compositions for modulating immune response |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432426A2 USE OF UNMETHYLATED CpG |
| 06/30/2004 | EP1432416A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1121146B1 Utilization of proteolytic enzymes to influence hyperactive t cells |
| 06/30/2004 | EP0971908B1 Il-8 receptor antagonists |
| 06/30/2004 | EP0690722B1 Composition and method for reducing toxicity of biologically-active factors |
| 06/30/2004 | CN1509337A New polynucleotides and polypeptides of IFN alpha-17 gene |
| 06/30/2004 | CN1509328A Use of opg ligand to modulate immune response |
| 06/30/2004 | CN1509327A CD4+CD25+regulatory T cells from human blood |
| 06/30/2004 | CN1509286A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509276A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509275A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509274A Metallo proteinase inhibitors |
| 06/30/2004 | CN1509273A Metalloproteinase inhibitors |
| 06/30/2004 | CN1509272A Metalloproteinase inhibitors |